FULC
Price
$6.44
Change
-$0.05 (-0.77%)
Updated
Aug 11, 02:44 PM (EDT)
Capitalization
351.05M
93 days until earnings call
RARE
Price
$27.54
Change
-$0.29 (-1.04%)
Updated
Aug 8 closing price
Capitalization
2.65B
85 days until earnings call
Interact to see
Advertisement

FULC vs RARE

Header iconFULC vs RARE Comparison
Open Charts FULC vs RAREBanner chart's image
Fulcrum Therapeutics
Price$6.44
Change-$0.05 (-0.77%)
Volume$300
Capitalization351.05M
Ultragenyx Pharmaceutical
Price$27.54
Change-$0.29 (-1.04%)
Volume$1.53M
Capitalization2.65B
FULC vs RARE Comparison Chart in %
Loading...
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FULC vs. RARE commentary
Aug 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FULC is a StrongBuy and RARE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 11, 2025
Stock price -- (FULC: $6.49 vs. RARE: $27.54)
Brand notoriety: FULC and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FULC: 58% vs. RARE: 71%
Market capitalization -- FULC: $351.05M vs. RARE: $2.65B
FULC [@Biotechnology] is valued at $351.05M. RARE’s [@Biotechnology] market capitalization is $2.65B. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FULC’s FA Score shows that 1 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • FULC’s FA Score: 1 green, 4 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, FULC is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FULC’s TA Score shows that 4 TA indicator(s) are bullish while RARE’s TA Score has 4 bullish TA indicator(s).

  • FULC’s TA Score: 4 bullish, 6 bearish.
  • RARE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RARE is a better buy in the short-term than FULC.

Price Growth

FULC (@Biotechnology) experienced а -4.98% price change this week, while RARE (@Biotechnology) price change was -3.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.49%. For the same industry, the average monthly price growth was +31.98%, and the average quarterly price growth was +19.31%.

Reported Earning Dates

FULC is expected to report earnings on Nov 12, 2025.

RARE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+22.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($2.65B) has a higher market cap than FULC($351M). FULC YTD gains are higher at: 38.085 vs. RARE (-34.538). FULC has higher annual earnings (EBITDA): -81.28M vs. RARE (-449.9M). RARE has more cash in the bank: 494M vs. FULC (214M). FULC has less debt than RARE: FULC (7.57M) vs RARE (38.3M). RARE has higher revenues than FULC: RARE (591M) vs FULC (0).
FULCRAREFULC / RARE
Capitalization351M2.65B13%
EBITDA-81.28M-449.9M18%
Gain YTD38.085-34.538-110%
P/E RatioN/AN/A-
Revenue0591M-
Total Cash214M494M43%
Total Debt7.57M38.3M20%
FUNDAMENTALS RATINGS
FULC vs RARE: Fundamental Ratings
FULC
RARE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
4993
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5036

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FULC's Valuation (24) in the null industry is somewhat better than the same rating for RARE (74) in the Biotechnology industry. This means that FULC’s stock grew somewhat faster than RARE’s over the last 12 months.

FULC's Profit vs Risk Rating (100) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to RARE’s over the last 12 months.

FULC's SMR Rating (97) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to RARE’s over the last 12 months.

FULC's Price Growth Rating (49) in the null industry is somewhat better than the same rating for RARE (93) in the Biotechnology industry. This means that FULC’s stock grew somewhat faster than RARE’s over the last 12 months.

FULC's P/E Growth Rating (100) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FULCRARE
RSI
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
69%
Momentum
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
77%
MACD
ODDS (%)
Bearish Trend 4 days ago
82%
Bullish Trend 4 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
83%
Advances
ODDS (%)
Bullish Trend 26 days ago
88%
Bullish Trend 11 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
73%
Bearish Trend 4 days ago
76%
Aroon
ODDS (%)
Bullish Trend 4 days ago
87%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LSCRX21.550.18
+0.84%
Loomis Sayles Small Cap Value Retail
JRASX91.330.58
+0.64%
Janus Henderson Research S
IOGYX41.290.14
+0.34%
Invesco Gold & Special Minerals R5
DNDGX19.77-0.10
-0.50%
Dunham Small Cap Growth N
PICMX61.69-1.20
-1.91%
Virtus KAR Mid-Cap Growth I

FULC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FULC has been loosely correlated with ANNX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then ANNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FULC
1D Price
Change %
FULC100%
-4.70%
ANNX - FULC
40%
Loosely correlated
-0.42%
VRDN - FULC
40%
Loosely correlated
-0.73%
RARE - FULC
39%
Loosely correlated
-1.04%
MRNA - FULC
38%
Loosely correlated
-1.84%
BMRN - FULC
38%
Loosely correlated
N/A
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with MREO. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
-1.04%
MREO - RARE
65%
Loosely correlated
-3.16%
TRDA - RARE
46%
Loosely correlated
-2.08%
REPL - RARE
46%
Loosely correlated
N/A
NRIX - RARE
46%
Loosely correlated
-2.28%
IDYA - RARE
45%
Loosely correlated
+3.08%
More